Bank of America Spends $250 Million a Year on Ozempic and Other GLP-1 Drugs, CEO Calls It 'a Good Investment'
Bank of America spends over $250 million yearly on GLP-1 drugs, with CEO Brian Moynihan calling it a smart investment.
Bank of America is spending a lot of money on weight-loss medicines for its employees because the company thinks it saves money overall by keeping workers healthier. When big companies spend money on employee health, it can signal they're thinking carefully about their future and costs.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.